5. Changes to the Affordable Care Act (ACA)— or repeal and replacement of ACA—should not impact Medicaid funding of treatment for substance use disorders (SUD).
“The Medicaid population contains a disproportionate share of individuals affected by SUD, and loss of coverage or funding for treatment of these individuals is likely to worsen the opioid abuse epidemic,” says Tyson Thompson, PharmD, a clinical consultant pharmacist in UMass Medical School’s Clinical Pharmacy Services.
“Treatment for SUD is costly; however, societal and healthcare costs that would result from individuals losing their access to treatment would likely be massive," Thompson says. "It is worth the cost to keep Medicaid patients in treatment for SUD from both a humanistic and pragmatic point of view.”